Literature DB >> 20594520

Superselective arterial chemotherapy for inoperable metastases in the dura mater and cranium.

S Suzuki1, A Kurata, H Takagi, K Nakahara, H Oka, Y Miyasaka, K Fujii.   

Abstract

SUMMARY: Diffuse metastases to the cranium and dura mater of the bilateral hemisphere do not allow surgical intervention. We describe an excellent case which was treated by intra-arterial chemotherapy using Epirubicine (Farumorbicine). A 58-year-old woman treated for breast cancer ten years ago was admitted to our hospital with headache and frontal mass lesions.Magnetic resonance (MR) imaging on admission revealed a remarkable enhanced lesion of the bilateral dura mater and cranium, and bilateral brain edema in the frontal lobe. Angiography disclosed a vascular rich tumour supplied by bilateral external carotid artery branches.We successfully treated the lesion using superselective intra-arterial chemotherapy with a minimal dose of Epirubicine followed by embolization of bilateral external carotid artery branches. Followup MR imaging two years after the endovascular treatment showed disappearance of the enhanced lesion and remodeling of the skull bone. The patient is neurologically free of symptoms.

Entities:  

Year:  2004        PMID: 20594520      PMCID: PMC3576605          DOI: 10.1177/159101990200800203

Source DB:  PubMed          Journal:  Interv Neuroradiol        ISSN: 1591-0199            Impact factor:   1.610


  11 in total

1.  Neoadjuvant intra-arterial infusion chemotherapy combined with hormonal therapy for locally advanced breast cancer.

Authors:  Y Yuyama; A Yagihashi; K Hirata; T Ohmura; Y Suzuki; J Okamoto; T Yamada; Y Okazaki; Y Watanabe; A Okazaki; K Toda; M Okazaki; T Yajima; H Kameshima; J Araya; N Watanabe
Journal:  Oncol Rep       Date:  2000 Jul-Aug       Impact factor: 3.906

2.  Intra-arterial cisplatin plus oral etoposide for the treatment of recurrent malignant glioma: a phase II study.

Authors:  L S Ashby; W R Shapiro
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

3.  Superselective arterial BCNU infusion in the treatment of patients with malignant gliomas.

Authors:  D A Clayman; S M Wolpert; D O Heros
Journal:  AJNR Am J Neuroradiol       Date:  1989 Jul-Aug       Impact factor: 3.825

4.  A phase II trial of high dose epirubicin in patients with advanced breast carcinoma.

Authors:  D K Miller; N Munshi; D Loesch; L E Einhorn; G W Sledge
Journal:  Cancer       Date:  2000-01-15       Impact factor: 6.860

5.  Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.

Authors:  J A Wils; J M Bliss; M Marty; G Coombes; C Fontaine; F Morvan; T Olmos; F R Pérez-López; P Vassilopoulos; E Woods; R C Coombes
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

6.  Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment.

Authors: 
Journal:  J Clin Oncol       Date:  2000-09       Impact factor: 44.544

7.  Superselective intra-arterial carboplatin for treatment of intracranial neoplasms: experience in 100 procedures.

Authors:  A I Qureshi; M F Suri; J Khan; M Sharma; K Olson; L R Guterman; L N Hopkins
Journal:  J Neurooncol       Date:  2001-01       Impact factor: 4.130

8.  Surgical treatment of brain metastases. Clinical and computerized tomography evaluation of the results of treatment.

Authors:  N Sundaresan; J H Galicich
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

9.  Arterial chemoembolization with microencapsulated anticancer drug. An approach to selective cancer chemotherapy with sustained effects.

Authors:  T Kato; R Nemoto; H Mori; M Takahashi; Y Tamakawa; M Harada
Journal:  JAMA       Date:  1981-03-20       Impact factor: 56.272

10.  Chemotherapy induces regression of brain metastases in breast carcinoma.

Authors:  D Rosner; T Nemoto; W W Lane
Journal:  Cancer       Date:  1986-08-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.